1Schon M, Bong AB, Drewniok C. Tumor - selective induction of apoptosis and the small - molecule immune response modifier imiquimod. J Natl Cancer Inst 2003 ; 95 (15) : 1138 - 1149.
2Dahl MV. Imiquimod: a cytokine inducer. J Am Acad Dermatol 2002 ; 47 (4 Suppl ) : 205 - 208.
3Tyring S, Conant M, Marini M. Imiquimod; an international update on therapeutic uses in dermatology.Int J Dermatol 2002 ; 41 ( 11 ) : 810- 816.
4Brady S, Wilson JD. Closing the feedback loop: an audit of the use of imiquimod forthe treatment of genital warts. JEADV 2004;18:314 -317.
5Suzuki H, Wang B, Shivji GM, et al. hniquimod, a topical immune response modifier, induces migration of Langerhans' cells. J Invest Dermatol 2000; 114( 1 ) : 135 - 141.
6Tomai MA, hnbertson LM, Stanczak TL, et al. The immune response modifiers imiquimod and R - 848 are potent activators of B lymphocytes. Cell Immunol,2000; 203 ( 1 ) : 55 - 56.
7Bernard HU. Established and potential strategies against papillomavirus infections. J Antimicrob Chemother 2004;53(2) : 137 - 139.
8Eedy DJ. hniquimod : a potential role in dermatology? Br J Dermatol 2002; 147( 1) : 1 - 6.
9O' Mahony C. Difficult wart cases- - use of imiquimod cream 5%. Int J STD AIDS 2001 ; 12(6) :400 - 403.
10Maw RD. Treatment of external genital warts with 5 % imiquimod cream during pregnancy: a case report. BJOG 2004; 111 (12): 1475.
